AI and CT-based prediction of immunotherapy response in lung cancer patients
Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)
This project will try to use CT scans and artificial intelligence to predict whether adults with lung cancer will respond to immunotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT07059923 on ClinicalTrials.gov |
What this trial studies
This observational project collects CT scans from adults with non-small cell or small cell lung cancer treated at Wuhan Union Hospital around the time they start immunotherapy. Automated tumor segmentation and radiomics feature extraction will be applied to the images, followed by feature selection and development of a machine-learning classification model to predict treatment response and survival. Clinical and pathological data will be combined with imaging features when available, and cases with poor image quality or incomplete follow-up will be excluded. The model will be trained and validated within this single-center cohort to explore whether imaging-based AI can help inform treatment decisions.
Who should consider this trial
Good fit: Adults (over 18) treated for lung cancer at Wuhan Union Hospital between July 2025 and July 2026 who have a pathological diagnosis and at least one pre-treatment CT scan are eligible.
Not a fit: Patients with poor-quality CT images, incomplete clinical data or follow-up, unclear pathology, or a second primary cancer are unlikely to benefit from the analysis.
Why it matters
Potential benefit: If successful, this approach could help doctors identify which patients are likely to benefit from immunotherapy and spare others unnecessary side effects.
How similar studies have performed: Previous radiomics and AI studies have shown promising retrospective results for predicting immunotherapy response, but findings remain preliminary and are not yet standard clinical practice.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients were treated for lung cancer in Wuhan Union Hospital from July 2025 to July 2026; 2. Aged \> 18 years old; 3. At least one CT scan before treatment; 4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors. Exclusion criteria: 1. Poor image quality; 2. Incomplete clinical data or loss of follow-up; 3. Presence of another primary malignancy other than lung cancer; 4. Unclear pathological diagnosis.
Where this trial is running
Wuhan, Hubei
- Union Hospital，Tongji Medical College，Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
Study contacts
- Study coordinator: Lian Yang
- Email: yanglian@hust.edu.cn
- Phone: 18986273791
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.